Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P N Münster

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pflugers Archiv : European Journal of Physiology|May 1, 1993
Effects of phorbol ester on gap junctions of neonatal rat heart cellsP N Münster, R Weingart
Hematology/Oncology Clinics of North America|June 11, 1999
Adjuvant therapy for resectable breast cancerP N Münster, C A Hudis
Seminars in Oncology|March 12, 1999
High-dose therapy for breast cancerC A Hudis, P N Münster
Cancer Research|April 18, 2001
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cellsP N Münster, M Srethapakdi, M M Moasser, et al.
Cell Biology International|December 22, 1999
Purification and characterization of a novel 35-kDa protein from transformed cardiomyocytesS Chandrasekhar, P N Münster, W A Henzel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001P N Münster, A Basso, D Solit, et al.
Cancer Research|April 29, 2000
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinasesF F Zheng, S D Kuduk, G Chiosis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancerP N Münster, A Buzdar, K Dhingra, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pflugers Archiv : European Journal of Physiology|May 1, 1993
Effects of phorbol ester on gap junctions of neonatal rat heart cellsP N Münster, R Weingart
Hematology/Oncology Clinics of North America|June 11, 1999
Adjuvant therapy for resectable breast cancerP N Münster, C A Hudis
Seminars in Oncology|March 12, 1999
High-dose therapy for breast cancerC A Hudis, P N Münster
Cancer Research|April 18, 2001
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cellsP N Münster, M Srethapakdi, M M Moasser, et al.
Cell Biology International|December 22, 1999
Purification and characterization of a novel 35-kDa protein from transformed cardiomyocytesS Chandrasekhar, P N Münster, W A Henzel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001P N Münster, A Basso, D Solit, et al.
Cancer Research|April 29, 2000
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinasesF F Zheng, S D Kuduk, G Chiosis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancerP N Münster, A Buzdar, K Dhingra, et al.
Pageof 1